BP-294 Ste Civile Bioprojet.
作者信息
Fozard J R
机构信息
Novartis Preclinical Research, Asthma Building 386/1035, Postfach, CH-4002 Basel, Switzerland.
出版信息
Curr Opin Investig Drugs. 2000 Sep;1(1):86-9.
PMID:11249601
Abstract
BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine H3 agonist under development by Bioprojet and in phase II clinical trials as an antiasthmatic [219798]. In a study, R-alpha-methylhistamine was shown to inhibit the release of acetylcholine, in the presence of atropine (1 microM) and 0.5 Hz of electrical stimulation of the rat bilateral vagus nerve, in a dose-dependent manner. This inhibition was abolished by thioperamide [321838].
摘要
相似文献
1
BP-294 Ste Civile Bioprojet.
Curr Opin Investig Drugs. 2000 Sep;1(1):86-9.
2
Carebastine Almirall Prodesfarma.
Curr Opin Investig Drugs. 2000 Sep;1(1):90-6.
3
PNU-142731A Pharmacia.
Curr Opin Investig Drugs. 2000 Dec;1(4):449-51.
4
ZD-0892 AstraZeneca.
Curr Opin Investig Drugs. 2000 Oct;1(2):227-9.
5
BP-294 (Ste Civile Bioprojet).
IDrugs. 2000 Aug;3(8):935-9.
6
Methylprednisolone suleptanate Pharmacia Corp.
Curr Opin Investig Drugs. 2000 Sep;1(1):97-103.
7
Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug.
J Pharmacol Exp Ther. 1997 Jun;281(3):1085-94.
8
BP-897 Bioprojet.
Curr Opin Investig Drugs. 2000 Sep;1(1):110-5.
9
[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives].
Yao Xue Xue Bao. 2004 Sep;39(9):705-10.
10
Pazufloxacin Toyama Chemical Co.
Curr Opin Investig Drugs. 2000 Sep;1(1):52-7.
Zotero 插件